Compare AbbVie Inc (ABBV) vs Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Price & Performance

AbbVie IncTrade

Direxion NASDAQ 100 Equal Weighted Index SharesTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? AbbVie Inc trades at $249.9 (market cap $441.94B), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $122.97. The key difference: AbbVie Inc pays a 2.77% dividend while Direxion NASDAQ 100 Equal Weighted Index Shares pays none, and Direxion NASDAQ 100 Equal Weighted Index Shares is trading nearer its 52-week high, AbbVie Inc nearer its low. Which is the better fit depends on your goals.

	ABBV	QQQE
Market Cap	$441.94B	—
Sector	Health	Broad Market / Factor
52-Week High	$263.58	$122.72
52-Week Low	$197.38	$96.06
Enterprise Value	$506.19B	—
Dividend Yield	2.77%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.

Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.

Direxion NASDAQ 100 Equal Weighted Index Shares

QQQE, the Direxion NASDAQ-100 Equal Weighted Index ETF, trades at $123.01, up 0.7% today, with a bullish technical signal from moving averages. The fund provides diversified exposure to the Nasdaq-100 with equal weighting, reducing concentration risk compared to cap-weighted peers. Recent news highlights its appeal as a defensive play amid tech-led market rallies and the upcoming inclusion of SpaceX in the index.

The outlook remains positive given equal-weight diversification benefits and strong Nasdaq-100 growth trends. Key risks include market volatility and sector concentration, but analyst sentiment favors QQQE for balanced Nasdaq exposure. The ETF's structure mitigates single-stock risk while capturing broad large-cap growth.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

ABBV

Fidelity Dividend ETF's payout is safe but not ideal for steady income due to variable quarterly dividends.24/7 Wall Street · 1 day agoNeutral Two Dividend Aristocrats outperformed the market while two lagged; three new picks show promising dividend growth.24/7 Wall Street · 2 days agoNeutral Healthcare sector leads S&P 500 gains over 3 months with key pharma stocks showing strong innovation and income potential.24/7 Wall Street · 2 days agoBullish View details →

QQQE

View details →

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

About Direxion NASDAQ 100 Equal Weighted Index Shares

QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.